{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:08:36Z","timestamp":1788973716762,"version":"build-2803163510"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.comppsych.2025.152616","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:16:40Z","timestamp":1752567400000},"page":"152616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Navigating the challenges of substance use and psychopathology in depression, bipolar disorder, and schizophrenia"],"prefix":"10.1016","volume":"142","author":[{"given":"Stefania","family":"Chiappini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Semeraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Amerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Berardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cremaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Di Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Pettorruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Dell'Osso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0005","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41398-022-02212-5","article-title":"Addictive and other mental disorders: a call for a standardized definition of dual disorders","volume":"12","author":"Szerman","year":"2022","journal-title":"Transl Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2025.152616_bb0010","first-page":"154","article-title":"Dual diagnosis: an intriguing and actual nosographic issue too long neglected","volume":"53","author":"Vitali","year":"2018","journal-title":"Riv Psichiatr"},{"key":"10.1016\/j.comppsych.2025.152616_bb0015","series-title":"ICD-11: International classification of diseases (11th revision)","author":"World Health Organization (WHO)","year":"2022"},{"key":"10.1016\/j.comppsych.2025.152616_bb0020","series-title":"Diagnostic and statistical manual of mental disorders","volume":"vol. 51","author":"American Psychiatric Publishing American Psychiatric Association","year":"2016"},{"key":"10.1016\/j.comppsych.2025.152616_bb0025","author":"NIDA"},{"issue":"6","key":"10.1016\/j.comppsych.2025.152616_bb0030","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1360-0443.2010.02902.x","article-title":"Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey","volume":"105","author":"Swendsen","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.comppsych.2025.152616_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.05.031","article-title":"Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: a systematic review and meta-analysis","volume":"154","author":"Lai","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/07067437241305174","article-title":"Substance use and concurrent disorders: current context and the need for treatment integration","volume":"70","author":"Hendershot","year":"2025","journal-title":"Can J Psychiatr"},{"issue":"8","key":"10.1016\/j.comppsych.2025.152616_bb0045","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/add.14599","article-title":"World Health Organization\u2019s World Mental Health Surveys collaborators. Cross-national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys","volume":"114","author":"Harris","year":"2019","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp053113","article-title":"Mood disorders and substance use disorder: a complex comorbidity","volume":"3","author":"Quello","year":"2005","journal-title":"Sci Pract Perspect"},{"key":"10.1016\/j.comppsych.2025.152616_bb0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jad.2020.01.141","article-title":"Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: systematic review and meta-analysis","volume":"266","author":"Hunt","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.comppsych.2025.152616_bb0060","doi-asserted-by":"crossref","first-page":"109551","DOI":"10.1016\/j.drugalcdep.2022.109551","article-title":"Prevalence of mental disorders among people with opioid use disorder: a systematic review and meta-analysis","volume":"238","author":"Santo","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.comppsych.2025.152616_bb0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/wps.20341","article-title":"Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis","volume":"15","author":"Murray","year":"2016","journal-title":"World Psychiatry"},{"key":"10.1016\/j.comppsych.2025.152616_bb0070","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neubiorev.2020.07.007","article-title":"Cannabis, nicotine and the negative symptoms of schizophrenia: systematic review and meta-analysis of observational studies","volume":"116","author":"Sabe","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"issue":"7","key":"10.1016\/j.comppsych.2025.152616_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11920-019-1044-x","article-title":"Cannabis and psychosis: are we any closer to understanding the relationship?","volume":"21","author":"Hamilton","year":"2019","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0080","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/add.14459","article-title":"Age-varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults","volume":"114","author":"Leadbeater","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.comppsych.2025.152616_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115053","article-title":"First episode psychosis with and without the use of cannabis and synthetic cannabinoids: psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness","volume":"320","author":"Ricci","year":"2023","journal-title":"Psychiatry Res"},{"issue":"23","key":"10.1016\/j.comppsych.2025.152616_bb0090","doi-asserted-by":"crossref","first-page":"12632","DOI":"10.3390\/ijerph182312632","article-title":"Duration of untreated disorder and Cannabis use: an observational study on a cohort of young Italian patients experiencing psychotic experiences and dissociative symptoms","volume":"18","author":"Ricci","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.comppsych.2025.152616_bb0095","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis","volume":"191","author":"Hunt","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.comppsych.2025.152616_bb0100","author":"Substance Abuse and Mental health Service Administration (SAMHSA)"},{"key":"10.1016\/j.comppsych.2025.152616_bb0105","series-title":"Comorbidity of substance use and mental disorders in Europe","author":"European Union Drugs Agency (EUDA)","year":"2016"},{"key":"10.1016\/j.comppsych.2025.152616_bb0110","series-title":"Common Comorbidities with Substance Use Disorders Research Report","year":"2020"},{"issue":"Suppl. 7","key":"10.1016\/j.comppsych.2025.152616_bb0115","first-page":"5","article-title":"Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness","volume":"67","author":"Buckley","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.comppsych.2025.152616_bb0120","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.2147\/NDT.S222567","article-title":"Co-occurring psychiatric and substance use disorders: clinical survey among a rural cohort of Italian patients","volume":"15","author":"Milano","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12888-021-03188-0","article-title":"Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review","volume":"21","author":"Alsuhaibani","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0130","article-title":"Significance of psychiatric comorbidity for the outcome of maintenance treatment - a review of the literature","volume":"4","author":"Schafer","year":"2011","journal-title":"Ment Health Subst Use"},{"issue":"3","key":"10.1016\/j.comppsych.2025.152616_bb0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S2045796015000347","article-title":"The prevalence and geographic distribution of complex co-occurring disorders: a population study","volume":"25","author":"Somers","year":"2016","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"7","key":"10.1016\/j.comppsych.2025.152616_bb0140","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/archgenpsychiatry.2011.2112","article-title":"Genetic and familial environmental influences on the risk for drug abuse: a national Swedish adoption study","volume":"69","author":"Kendler","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.comppsych.2025.152616_bb0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.schres.2017.04.016","article-title":"The link between schizophrenia and substance use disorder: A unifying hypothesis","volume":"194","author":"Khokhar","year":"2018","journal-title":"Schizophr Res"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0150","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic advances from the brain disease model of addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"N Engl J Med"},{"issue":"9904","key":"10.1016\/j.comppsych.2025.152616_bb0155","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(13)61530-5","article-title":"Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Degenhardt","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.comppsych.2025.152616_bb0160","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn.2016.57","article-title":"Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression","volume":"17","author":"Grace","year":"2016","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0893-133X(00)00195-0","article-title":"Drug addiction, dysregulation of reward, and allostasis","volume":"24","author":"Koob","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0170","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/S1092852920001479","article-title":"Substance-related exogenous psychosis: a postmodern syndrome","volume":"26","author":"Martinotti","year":"2021","journal-title":"CNS Spectr"},{"issue":"6","key":"10.1016\/j.comppsych.2025.152616_bb0175","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0306-4603(98)00073-2","article-title":"Dual diagnosis: a review of etiological theories","volume":"23","author":"Mueser","year":"1998","journal-title":"Addict Behav"},{"key":"10.1016\/j.comppsych.2025.152616_bb0180","author":"UNODC"},{"key":"10.1016\/j.comppsych.2025.152616_bb0185","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)"},{"issue":"8","key":"10.1016\/j.comppsych.2025.152616_bb0190","first-page":"2406","article-title":"Concurrent disorder management guidelines","volume":"9","author":"Hakobyan","year":"2020","journal-title":"Syst Rev J Clin Med"},{"issue":"7","key":"10.1016\/j.comppsych.2025.152616_bb0195","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","article-title":"BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP","volume":"26","author":"Lingford-Hughes","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.comppsych.2025.152616_bb0200","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"10.1016\/j.comppsych.2025.152616_bb0205","author":"National Institute for Health and Care Excellence (NICE)"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0210","first-page":"88","article-title":"Treatment for substance use disorder with co-occurring mental illness","volume":"17","author":"Iqbal","year":"2019","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"10.1016\/j.comppsych.2025.152616_bb0215","article-title":"PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.comppsych.2025.152616_bb0220","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"27","key":"10.1016\/j.comppsych.2025.152616_bb0225","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2174\/1381612828666220623092853","article-title":"Atypical antipsychotic drugs in dual disorders: current evidence for clinical practice","volume":"28","author":"Martinotti","year":"2022","journal-title":"Curr Pharm Des"},{"issue":"1\u20133","key":"10.1016\/j.comppsych.2025.152616_bb0230","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2014.03.002","article-title":"Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine","volume":"155","author":"Mesholam-Gately","year":"2014","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0235","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881111408957","article-title":"Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine","volume":"26","author":"Machielsen","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"1\u20132","key":"10.1016\/j.comppsych.2025.152616_bb0240","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15504263.2011.570118","article-title":"A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia","volume":"7","author":"Brunette","year":"2011","journal-title":"J Dual Diagn"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0245","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/sbl003","article-title":"Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders","volume":"32","author":"Brunette","year":"2006","journal-title":"Schizophr Bull"},{"issue":"7","key":"10.1016\/j.comppsych.2025.152616_bb0250","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0269881114527357","article-title":"The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: an fMRI study","volume":"28","author":"Machielsen","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"3","key":"10.1016\/j.comppsych.2025.152616_bb0255","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1521-0391.2014.12126.x","article-title":"Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study","volume":"23","author":"Schnell","year":"2014","journal-title":"Am J Addict"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0260","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.pnpbp.2008.01.009","article-title":"Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia","volume":"32","author":"Kim","year":"2008","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.comppsych.2025.152616_bb0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2007.11.034","article-title":"The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study","volume":"100","author":"Swartz","year":"2008","journal-title":"Schizophr Res"},{"issue":"7","key":"10.1016\/j.comppsych.2025.152616_bb0270","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/NMD.0000000000000317","article-title":"Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia","volume":"203","author":"Mohamed","year":"2015","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.comppsych.2025.152616_bb0275","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3389\/fphar.2018.00769","article-title":"Risperidone provides better improvement of sleep disturbances than haloperidol therapy in schizophrenia patients with cannabis-positive urinalysis","volume":"9","author":"Thomas-Brown","year":"2018","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0280","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/jnp.2008.20.1.117","article-title":"Aripiprazole diminishes cannabis use in schizophrenia","volume":"20","author":"Desseilles","year":"2008","journal-title":"J Neuropsychiatr Clin Neurosci"},{"issue":"6","key":"10.1016\/j.comppsych.2025.152616_bb0285","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/JCP.0000000000000794","article-title":"Effective switch from clozapine to aripiprazole in treatment-resistant schizophrenia and comorbid alcohol use disorder","volume":"37","author":"Feeley","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.comppsych.2025.152616_bb0290","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/JCP.0000000000000789","article-title":"Late reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs perphenazine in schizophrenia and comorbid cocaine dependence","volume":"37","author":"Beresford","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"10.1016\/j.comppsych.2025.152616_bb0295","article-title":"Case report: cariprazine in a patient with schizophrenia, substance abuse, and cognitive dysfunction","author":"Rodriguez Cruz","year":"2021","journal-title":"Front Psychol"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0300","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JCP.0b013e318166f520","article-title":"Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis","volume":"28","author":"van Nimwegen","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.comppsych.2025.152616_bb0305","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/070674370805300610","article-title":"Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial","volume":"53","author":"van Nimwegen","year":"2008","journal-title":"Can J Psychiatr"},{"issue":"23","key":"10.1016\/j.comppsych.2025.152616_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph192316057","article-title":"Lurasidone use in cannabis-induced psychosis: a novel therapeutic strategy and clinical considerations in four cases report","volume":"19","author":"Ricci","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"2\u20133","key":"10.1016\/j.comppsych.2025.152616_bb0315","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.schres.2008.08.010","article-title":"Successful acamprosate treatment of alcohol dependence in schizophrenia","volume":"106","author":"Tek","year":"2008","journal-title":"Schizophr Res"},{"issue":"1\u20132","key":"10.1016\/j.comppsych.2025.152616_bb0320","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/15504263.2011.569440","article-title":"Treatment with acamprosate in patients with schizophrenia spectrum disorders and comorbid alcohol dependence","volume":"7","author":"Ralevski","year":"2011","journal-title":"J Dual Diagn"},{"issue":"7","key":"10.1016\/j.comppsych.2025.152616_bb0325","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.clinthera.2017.05.356","article-title":"Impact of Paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia and comorbid substance abuse","volume":"39","author":"Lefebvre","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.comppsych.2025.152616_bb0330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2017.05.005","article-title":"Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: an exploratory analysis of the PRIDE study","volume":"194","author":"Lynn Starr","year":"2018","journal-title":"Schizophr Res"},{"issue":"8","key":"10.1016\/j.comppsych.2025.152616_bb0335","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/070674370605100808","article-title":"Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity","volume":"51","author":"Rubio","year":"2006","journal-title":"Can J Psychiatr"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0340","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40801-020-00178-8","article-title":"Once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and co-occurring substance use disorders: a multicentre","volume":"7","author":"Szerman","year":"2020","journal-title":"Observ Study Drugs Real World Outcomes"},{"issue":"5","key":"10.1016\/j.comppsych.2025.152616_bb0345","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/JCP.0000000000001087","article-title":"Long-acting injectable aripiprazole for a schizophrenic patient concomitant with stimulant use disorder","volume":"39","author":"Chen","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2025.152616_bb0350","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/NDT.S171002","article-title":"Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life","volume":"14","author":"Cuomo","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.comppsych.2025.152616_bb0355","first-page":"102","article-title":"Successful treatment with long-acting injectable aripiprazole monohydrate for two patients with dual diagnosis - substance use disorder and psychotic disorder","volume":"34","author":"Erdogan","year":"2021","journal-title":"Dusunen Adam J Psychiatry Neurol Sci"},{"key":"10.1016\/j.comppsych.2025.152616_bb0360","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2147\/NDT.S418627","article-title":"Efficacy of psychosocial and psychological interventions in addition to drug therapy to improve global functioning of inpatients with schizophrenia spectrum and mood disorders: a real-world observational study","volume":"19","author":"Chiappini","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"10","key":"10.1016\/j.comppsych.2025.152616_bb0365","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3928\/02793695-20081001-05","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D). Part 2: study outcomes","volume":"46","author":"Howland","year":"2008","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"10.1016\/j.comppsych.2025.152616_bb0370","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.psychres.2016.06.005","article-title":"Mirtazapine in comorbid major depression and an alcohol use disorder: a double-blind placebo-controlled pilot trial","volume":"242","author":"Cornelius","year":"2016","journal-title":"Psychiatry Res"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0375","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/hup.935","article-title":"Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study","volume":"23","author":"Altintoprak","year":"2008","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0380","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/da.20918","article-title":"Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial","volume":"29","author":"Davis","year":"2012","journal-title":"Depress Anxiety"},{"issue":"11","key":"10.1016\/j.comppsych.2025.152616_bb0385","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2174\/1570159X21666230403080624","article-title":"Update on pharmacological treatment for comorbid major depressive and alcohol use disorders: the role of extended-release trazodone","volume":"21","author":"Di Nicola","year":"2023","journal-title":"Curr Neuropharmacol"},{"issue":"9","key":"10.1016\/j.comppsych.2025.152616_bb0390","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1530-0277.2008.00742.x","article-title":"Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial","volume":"32","author":"Friedmann","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"issue":"12","key":"10.1016\/j.comppsych.2025.152616_bb0395","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.2174\/1570159X19666210113150123","article-title":"Vortioxetine vs. other antidepressants in patients with major depressive episode with or without substance use disorder","volume":"19","author":"Kotzalidis","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.comppsych.2025.152616_bb0400","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1747-597X-3-20","article-title":"Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication","volume":"3","author":"Muhonen","year":"2008","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"6","key":"10.1016\/j.comppsych.2025.152616_bb0405","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/JCP.0b013e3182726764","article-title":"A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder","volume":"32","author":"Witte","year":"2012","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.comppsych.2025.152616_bb0410","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.2009.08060852","article-title":"A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence","volume":"167","author":"Pettinati","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2025.152616_bb0415","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.comppsych.2025.152616_bb0420","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"10.1016\/j.comppsych.2025.152616_bb0425","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/07067437221145013","article-title":"Effects of Buprenorphine\/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial","volume":"68","author":"Bastien","year":"2023","journal-title":"Can J Psychiatr"},{"key":"10.1016\/j.comppsych.2025.152616_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108996","article-title":"Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone","volume":"228","author":"Zhu","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0435","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/00952990.2010.540281","article-title":"The association between naltrexone treatment and symptoms of depression in opioid-dependent patients","volume":"37","author":"Mysels","year":"2011","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"5","key":"10.1016\/j.comppsych.2025.152616_bb0440","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/YIC.0000000000000223","article-title":"A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder","volume":"33","author":"El Hage","year":"2018","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"10.1016\/j.comppsych.2025.152616_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19127397","article-title":"Trazodone prolonged-release monotherapy in cannabis dependent patients during lockdown due to COVID-19 pandemic: a case series","volume":"19","author":"Mazza","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0450","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00213-019-05384-z","article-title":"Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder","volume":"237","author":"Tomko","year":"2020","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"10.1016\/j.comppsych.2025.152616_bb0455","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drugalcdep.2010.05.010","article-title":"Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults","volume":"112","author":"Cornelius","year":"2010","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0460","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/00952990.2011.644002","article-title":"The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression","volume":"38","author":"Afshar","year":"2012","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0465","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1521-0391.2013.12065.x","article-title":"A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients","volume":"23","author":"Raby","year":"2014","journal-title":"Am J Addict"},{"issue":"11","key":"10.1016\/j.comppsych.2025.152616_bb0470","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1530-0277.2009.01024.x","article-title":"A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence","volume":"33","author":"Brown","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"10.1016\/j.comppsych.2025.152616_bb0475","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1530-0277.2011.01645.x","article-title":"Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate","volume":"36","author":"Prisciandaro","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0480","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4088\/JCP.07m04022","article-title":"A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence","volume":"70","author":"Kemp","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.comppsych.2025.152616_bb0485","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hup.944","article-title":"Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics","volume":"23","author":"Martinotti","year":"2008","journal-title":"Hum Psychopharmacol"},{"issue":"15","key":"10.1016\/j.comppsych.2025.152616_bb0490","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00213-017-4642-5","article-title":"A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use","volume":"234","author":"Gao","year":"2017","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.comppsych.2025.152616_bb0495","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/j.1530-0277.2010.01270.x","article-title":"A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence","volume":"34","author":"Stedman","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0500","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/ajad.12346","article-title":"A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder","volume":"25","author":"Sylvia","year":"2016","journal-title":"Am J Addict"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0505","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/00952990.2015.1114118","article-title":"An open-label pilot study of icariin for co-morbid bipolar and alcohol use disorder","volume":"42","author":"Xiao","year":"2016","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"6","key":"10.1016\/j.comppsych.2025.152616_bb0510","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/acer.13640","article-title":"Add-on memantine treatment for bipolar II disorder comorbid with alcohol dependence: a 12-week follow-up study","volume":"42","author":"Lee","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.comppsych.2025.152616_bb0515","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euroneuro.2020.12.006","article-title":"A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder","volume":"43","author":"Sherwood Brown","year":"2021","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"10.1016\/j.comppsych.2025.152616_bb0520","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/npp.2012.90","article-title":"A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence","volume":"37","author":"Brown","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.comppsych.2025.152616_bb0525","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jad.2012.05.006","article-title":"A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence","volume":"143","author":"Brown","year":"2012","journal-title":"J Affect Disord"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0530","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/WNF.0000000000000011","article-title":"Bupropion as an add-on therapy in depressed bipolar disorder type I patients with comorbid cocaine dependence","volume":"37","author":"Sepede","year":"2014","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0535","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13085","article-title":"Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders","volume":"27","author":"Prisciandaro","year":"2022","journal-title":"Addict Biol"},{"issue":"5","key":"10.1016\/j.comppsych.2025.152616_bb0540","doi-asserted-by":"crossref","first-page":"362","DOI":"10.5055\/jom.2019.0525","article-title":"A double blind randomized clinical trial of buprenorphine augmentation for treatment of psychotic symptoms in opioid addicted bipolar patients","volume":"15","author":"Khalili","year":"2019","journal-title":"J Opioid Manag"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0545","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/08897077.2013.814615","article-title":"Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: an 8-week, open-label, uncontrolled, preliminary study","volume":"35","author":"Bruno","year":"2014","journal-title":"Subst Abus"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0550","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/10550887.2021.1905589","article-title":"Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study","volume":"39","author":"Skryabin","year":"2021","journal-title":"J Addict Dis"},{"key":"10.1016\/j.comppsych.2025.152616_bb0555","first-page":"575","article-title":"Patterns of Management of Patients with dual disorder (psychosis) in Italy: a survey of psychiatrists and other physicians focusing on clinical practice","volume":"9","author":"Clerici","year":"2018","journal-title":"Front Psychol"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0560","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/YCO.0000000000000510","article-title":"Treatment of substance use disorders with co-occurring severe mental health disorders","volume":"32","author":"Murthy","year":"2019","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.comppsych.2025.152616_bb0565","series-title":"Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications","author":"Stahl","year":"2013"},{"issue":"5","key":"10.1016\/j.comppsych.2025.152616_bb0570","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0897190021997011","article-title":"Lurasidone for adolescents with complex mental disorders: a case series","volume":"35","author":"Mole","year":"2022","journal-title":"J Pharm Pract"},{"issue":"5","key":"10.1016\/j.comppsych.2025.152616_bb0575","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/1871527316666170413113246","article-title":"Cannabis; epidemiological, neurobiological and psychopathological issues: an update","volume":"16","author":"De Luca","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"5","key":"10.1016\/j.comppsych.2025.152616_bb0580","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","article-title":"The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study","volume":"6","author":"Di Forti","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2025.152616_bb0585","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in South London with first-episode psychosis attributable to use of high potency cannabis: a case-control study","volume":"2","author":"Di Forti","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.comppsych.2025.152616_bb0590","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/schbul\/sbt181","article-title":"Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users","volume":"40","author":"Di Forti","year":"2014","journal-title":"Schizophr Bull"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0595","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1017\/S0033291719003532","article-title":"Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016","volume":"51","author":"Hjorth\u00f8j","year":"2021","journal-title":"Psychol Med"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0600","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1176\/appi.ajp.2017.17020223","article-title":"Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis","volume":"175","author":"Starzer","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2025.152616_bb0605","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)"},{"issue":"10","key":"10.1016\/j.comppsych.2025.152616_bb0610","first-page":"851","article-title":"The bridge between classical and \u201csynthetic\u201d\/chemical psychoses: towards a clinical, psychopathological, and therapeutic perspective","author":"Orsolini","year":"2019","journal-title":"Front Psychol"},{"issue":"7","key":"10.1016\/j.comppsych.2025.152616_bb0615","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/brainsci8070133","article-title":"Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues","volume":"8","author":"Bonaccorso","year":"2018","journal-title":"Brain Sci"},{"issue":"5","key":"10.1016\/j.comppsych.2025.152616_bb0620","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2174\/1871527316666170413101839","article-title":"Synthetic cannabinoids: psychopharmacology, clinical aspects, psychotic onset","volume":"16","author":"Martinotti","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"3","key":"10.1016\/j.comppsych.2025.152616_bb0625","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2174\/1570159X22666240827165327","article-title":"Major depression in comorbidity with substance use disorders: patients\u2019 features and clinical-neurobiological rationale of antidepressant treatments","volume":"23","author":"De Filippis","year":"2025","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0630","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/oxfordjournals.alcalc.a008405","article-title":"Adjuvant trazodone in the treatment of alcoholism: an open study","volume":"33","author":"Janiri","year":"1998","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"10.1016\/j.comppsych.2025.152616_bb0635","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/0004867413508455","article-title":"Anhedonia in substance use disorders: a systematic review of its nature, course and clinical correlates","volume":"48","author":"Garfield","year":"2014","journal-title":"Aust N Z J Psychiatry"},{"issue":"07","key":"10.1016\/j.comppsych.2025.152616_bb0640","doi-asserted-by":"crossref","DOI":"10.4236\/ijcm.2012.37125","article-title":"Anhedonia and reward system: psychobiology, evaluation, and clinical features","volume":"03","author":"Martinotti","year":"2012","journal-title":"Int J Clin Med"},{"key":"10.1016\/j.comppsych.2025.152616_bb0645","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3389\/fpsyt.2019.00621","article-title":"rTMS stimulation group. rTMS reduces psychopathological burden and cocaine consumption in treatment-seeking subjects with cocaine use disorder: an open label, feasibility study","volume":"10","author":"Pettorruso","year":"2019","journal-title":"Front Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0650","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/00952990.2016.1200592","article-title":"Treatment of substance use disorders in schizophrenia","volume":"43","author":"Bennett","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"10.1016\/j.comppsych.2025.152616_bb0655","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamapsychiatry.2018.3537","article-title":"Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study","volume":"76","author":"Latif","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.comppsych.2025.152616_bb0660","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3390\/ijms19082410","article-title":"The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review","volume":"19","author":"Serafini","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.comppsych.2025.152616_bb0665","first-page":"68","article-title":"Toward the identification of a specific psychopathology of substance use disorders","author":"Maremmani","year":"2017","journal-title":"Front Psychol"},{"key":"10.1016\/j.comppsych.2025.152616_bb0670","author":"Lunsky"},{"issue":"4","key":"10.1016\/j.comppsych.2025.152616_bb0675","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/00952990.2017.1292279","article-title":"Management of comorbid bipolar disorder and substance use disorders","volume":"43","author":"Salloum","year":"2017","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X25000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X25000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T04:47:20Z","timestamp":1756442840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X25000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":135,"alternative-id":["S0010440X25000446"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2025.152616","relation":{},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating the challenges of substance use and psychopathology in depression, bipolar disorder, and schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Comprehensive Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.comppsych.2025.152616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152616"}}